ABO Sequence Analysis in an AB Type with Anti-B Patient
Chen Qing,Xiao Jianyu,Wang Shuya,Li Jiahuang,Du Leilei,Lu Le,Huang Chengyin,Li Min,Li Ping
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20132770
IF: 6.133
2014-01-01
Chinese Medical Journal
Abstract:ABO blood group system is the first to be discovered and the most clinically important in transfusion medicine.1 The ABO gene encodes a glycosyltransferase which synthesize the oligosaccharide epitopes. The difference between the consensus A gene (A101 allele) usually used as the reference and the consensus B gene (B101 allele) are 7 in-frame single nucleotide polymorphisms (SNPs), among which only 4 alleles cause amino acid mutations in the enzyme. When A allele was inherited from one parent and B allele was inherited from the other which produced the AB blood group, this is known as trans-AB. Cis-AB is characterized as mutant ABO alleles encoding a glycosyltransferase capable of synthesizing both A and B antigens which is very rare. ABO typing discrepancy was occasionally seen in clinic. Here, we reported an analysis of all the exons of the ABO gene of one case with forward typing and reverse typing discrepancy referred to our lab to identify the ABO molecular genetic basis of this patient. METHODS Blood sample A 56-year-old female patient was admitted to Drum Tower Hospital due to the multiple stones in her left kidney and was discovered an ABO typing discrepancy. Genomic DNA was extracted using TIANamp Blood DNA Kit (Tiangen, China). Serologic test The forward typing was performed with anti-A and anti-B by gel test (DiaClon ABO/D + reverse grouping for patients, DiaMed GmbH, Switzerland) and manual tube test using monoclonal anti-A, anti-B, anti-A1, anti-H, and anti-AB antisera (Shanghai Hemo-Pharmaceutical & Biological, Inc., Shanghai, China) according to standard protocols. The reverse typing was also performed by the gel test and the tube method using A cells and B cells. Amplification of theABOgene The exon 1 to exon 5 were amplified and sequenced according to the method published previously.2 Amplification of the ABO exon 6 to 7 and adjacent introns were carried out in a final volume of 50 μl, containing 1 μl of DNA, 0.25 mmol/L of each dNTP, 1.25 U Taq polymerase (Thermo Fisher Scientific Inc., USA), 5 μl PCR-buffer 10× with 1.5 mmol/L MgCl2, 0.2 μmol/L each of sense primer (1F 5′-CCCTTTGCTTTCTCTGACTTGCG-3′) and antisense primer (1R 5′-AGTTACTCACAACAGGACGGACA-3′). Thermal cycler conditions consisted of an initial denaturation of 2 minutes at 95°C, followed by 35 cycles of 30 seconds denaturation at 95°C and 30 seconds annealing 59°C, 3 minutes extension at 72°C, and finally 7 minutes extension at 72°C. ABOexons sequencing PCR products were purified by a commercial kit (Axygen, USA). Nucleotide sequencing was performed with a DNA sequencing unit (Applied Biosystems, USA). Sequences primers for exon 6 and exon 7 were: 2F: 5′-CCTGCCAGCTCCATGTGACC-3′; 2FS: 5′-GGGCAGGAGAACGTGGTGCAT-3′ and 1R. Capillary electrophoresis and data collections were carried out on the ABI PRISM 3730XL Genetic Analyzer (Applied Biosystems). Exons 6 and 7 cloning sequencing PCR products of exons 6 and 7 were subcloned into a TA-cloning vector (Invitrogen, USA) and transformed into Escherichia coli DH5 competent cells. Plasmids were isolated using the Wizard Plus Mini Prep DNA purification system (Promega, USA). Inserts were sequenced with a cycle sequencing kit and a DNA sequencer. Three dimensional structure modeling Based on the structure of wide type human N-acetylgalacto-saminyl transferase (PDB code: 1ZI5), the structure of mutants P156L and G268A was generated using Discovery Studio 2.5 (AccelrysSoftware Inc., USA) and optimized through a 1 000-step energy minimization. RESULTS Serologic test The forward type showed that A and weak B antigens are present on the RBCs of the patient; the reverse type showed anti-B in the patient's serum. Sequence analysis In ABO exon 7, this patient sample were heterozygous for a C>T exchange at position 467 and a G>C exchange at position 803 which resulted in a Pro to Leu substitution and a Gly to Arg substitution at codon 156 and 268 in the ABO protein, respectively. In this study, the variant (467 C>T, 803 G>C) allele expressed an ABweak phenotype with anti-B in her serum with an ABO*cis-AB01 / O01 heterozygote genotype. Exon 6 and 7 cloning sequencing confirmed that these two independents SNPs observed belonged to one allele. Homology modeling of the cis-AB01 enzyme structure Three-dimensional structure modeling of cis-AB01 enzyme suggests that mutation G268A may change the conformation around substrate binding sites, typically Asp211 and Glu303, and affect the interactions of the enzyme to ligands (Figure 1A). P156 is away from the active site of enzyme and seems not related to the acceptor substrate binding (Figure 1B).Figure 1.: Homology modeling of the crystal structure of human GTA and cisAB-01 (P156L, G268A) complexed with H type acceptor. Zoom in local structures around the G268A mutation (A) and P156L mutation (B), respectively. Substrates are colored in green.DISCUSSION In this study, the patient carried the cis-AB01 allele differed from the normal A101 allele only by 2 nucleotide substitutions causing two amino acids change at position Pro156Leu and Gly268Ala, respectively.1,3 To date, 8 subtypes of cis-AB were reported which are characterized as an interchange of amino acids between the normal A enzyme sequence and its B counterpart, and co-expressed both antigens.1 The frequency of cis-AB01 allele is about 0.0012% in Japan1 and 0.0354% in Korean donors, respectively.3 Pro156Leu is common in Asians1 and likely donot affect the function of the enzyme (Figure 1B).4 Gly268Ala is involved in the substitution of the A-transferase-specific glycine residue with a B-transferase-specific alanine which results in a bifunctional transferase.1 Three-dimensional molecular modeling of the cis-AB01 enzymes suggests that the Gly268Ala mutations might cause conformational change and affect acceptor substance binding (Figure 1A). The genetics of ABO is diversified and complex,5 for example, some seemingly identical phenotypes result from different molecular genetic background while a certain allele can result in more than one phenotype.1,5 Additionally, altered ABO expression in hematologic disorders, especially in the myeloid lineage malignancy was observed in clinic.1 Therefore, ABO genotyping provides an independent addition to serology to support clinical decisions in the reference laboratory. Our study confirmed that genotyping is useful in solving ABO serological discrepancy. Additionally, with the increasing price of serologic reagents, molecular typing also can be cost efficiently. ABO genotyping is needed for correct identification subgroups to improve the accuracy evaluation of blood typing and to increase the safety of blood transfusion.